Showing posts with the label Ascendis Pharma

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Ascendis Pharma today announced the European Commission (EC) has granted Orphan Designation to TransCon PTH for the treatment of hypoparathyroidism (HP). TransCon PTH is an investigational once-daily…
Subscribe Our Newsletter